# A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib

> **NCT01645085** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 88 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MCC-based 13% drug loaded tablets
- **DRUG:** Mannitol-based 38% drug-loaded tablet
- **DRUG:** MCC-based 13% drug loaded tablets
- **DRUG:** Mannitol-based 38% drug-loaded tablet

## Key facts

- **NCT ID:** NCT01645085
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2013-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01645085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01645085, "A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01645085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*